Testosterone undecanoate is associated with improved ageing male symptoms score in men with type 2 diabetes and adult-onset testosterone deficiency: re-analyzed results from a randomised controlled trial

Pravinath Ramachandran , Michael Zitzmann , Carola S. König , Joseph Mulhern , Sudarshan Ramachandran , Geoffrey Hackett

Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (4) : 177 -90.

PDF (1819KB)
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (4) :177 -90. DOI: 10.37349/eemd.2024.00015
Original Article
research-article
Testosterone undecanoate is associated with improved ageing male symptoms score in men with type 2 diabetes and adult-onset testosterone deficiency: re-analyzed results from a randomised controlled trial
Author information +
History +
PDF (1819KB)

Abstract

Aim: To evaluate changes in quality of life via the ageing male symptom scale (AMSS) and somatic, psychological, and sexual sub-scales following testosterone undecanoate (TU) or placebo (P) treatment in men with type 2 diabetes mellitus (T2DM) and adult-onset testosterone deficiency (TD) via a re-analysis of the BLAST (Burntwood, Lichfield, Atherstone, Sutton Coldfield, and Tamworth) randomised controlled trial (RCT). Methods: Analysis of data from the BLAST RCT in men with T2DM and adult-onset TD was performed. Summation baseline and study-end AMSS data were available in 170 men (94: P; 76: TU) with subscale data available in 82 men. Rank-sum and sign-rank tests determined inter/intra-group differences, whilst linear/multiple regression models identified predictors of AMSS change. Results: AMSS improved significantly in P [–2 (median), p = 0.010] and TU [–6 (median), p < 0.0001)] arms, with greater improvement observed in men on TU ( p = 0.014). No significant change was seen in either arm with baseline AMSS < 27 (asymptomatic). TU was significantly associated with AMSS improvement in all symptomatic AMSS categories. Improvement in the P arm was confined to men with baseline AMSS > 49. In the cohort with subscale AMSS data, TU was associated with improvements in somatic, psychological, and sexual subscales, whilst improvement was limited to the somatic subscale in the men on P. TU (reference: P) and higher baseline AMSS were significantly and independently associated with AMSS improvement. The improvement in summation AMSS associated with TU (reference: P) was only evident in men with mild depression and no anxiety (based on baseline Hospital Anxiety and Depression Scale data). Conclusions: TU appeared associated with improved AMSS (summation and subscales) in men with T2DM and adult-onset TD demonstrating symptoms (AMSS ≥ 27) with this benefit mediated by levels of depression and anxiety (European Union Clinical Trials Register, EudraCT 2008-000931-16).

Keywords

Ageing male symptoms score / hospital anxiety and depression scale / testosterone therapy / type 2 diabetes / adult-onset hypogonadism

Cite this article

Download citation ▾
Pravinath Ramachandran, Michael Zitzmann, Carola S. König, Joseph Mulhern, Sudarshan Ramachandran, Geoffrey Hackett. Testosterone undecanoate is associated with improved ageing male symptoms score in men with type 2 diabetes and adult-onset testosterone deficiency: re-analyzed results from a randomised controlled trial. Exploration of Endocrine and Metabolic Diseases, 2024, 1 (4) : 177-90 DOI:10.37349/eemd.2024.00015

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Hackett G, Kirby M, Rees RW, Jones TH, Muneer A, Livingston M, et al. The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice. World J Mens Health. 2023; 41: 508-37.

[2]

Antonio L, Wu FCW, Moors H, Matheï C, Huhtaniemi IT, Rastrelli G, et al.; EMAS Study Group. Erectile dysfunction predicts mortality in middle-aged and older men independent of their sex steroid status. Age Ageing. 2022; 51: afac094.

[3]

Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007; 30: 911-7.

[4]

Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. EAU Guidelines on Male Hypogonadism [Internet]. European Association of Urology; c2019 [cited 2023 Dec 12]. Available from: https://d56bochluxqnz.cloudfront.net/media/EAU-Guidelines-on-Male-Hypogonadism-2019v2.pdf

[5]

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Lessons From the Testosterone Trials. Endocr Rev. 2018; 39: 369-86.

[6]

Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020; 8: 1598-605.

[7]

Lunenfeld B, Mskhalaya G, Kalinchenko S, Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male. 2013; 16: 143-50.

[8]

Heinemann LAJ, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males’ Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003; 1: 15.

[9]

Akehi Y, Tanabe M, Yano H, Takashi Y, Kawanami D, Nomiyama T, et al. A simple questionnaire for the detection of testosterone deficiency in men with late-onset hypogonadism. Endocr J. 2022; 69: 1303-12.

[10]

Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015; 18: 5-15.

[11]

Morley JE, 3rd HMP, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006; 53: 424-9.

[12]

Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017; 7:e015284.

[13]

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013; 10: 1612-27.

[14]

Stern AF. The hospital anxiety and depression scale. Occup Med (Lond). 2014; 64: 393-4.

[15]

Behre HM, Tammela TLJ, Arver S, Tolrá JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012; 15: 198-207.

[16]

Lee C, Jiang J, Chen Y, Chu C, Hsu S, Chen C, et al. The “Aging Males’ Symptoms” (AMS) Scale assesses depression and anxiety. Aging Male. 2013; 16: 97-101.

[17]

Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: An updated literature review. J Psychosom Res. 2002; 52: 69-77.

[18]

Borst SE, Yarrow JF, Fernandez C, Conover CF, Ye F, Meuleman JR, et al. Cognitive effects of testosterone and finasteride administration in older hypogonadal men. Clin Interv Aging. 2014; 9: 1327-33.

[19]

Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003; 160: 105-11.

[20]

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al.; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016; 374: 611-24.

[21]

Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010; 7: 2572-82.

[22]

Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019; 76: 31-40.

[23]

Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, et al. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. Lancet Healthy Longev. 2023; 4: e561-72.

[24]

Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pre-treatment value determines post-treatment response. Eur Heart J. 2015; 36: 576-9.

[25]

Chantzaras A, Yfantopoulos J. Association between medication adherence and health-related quality of life of patients with diabetes. Hormones (Athens). 2022; 21: 691-705.

[26]

Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, et al.; Blast Study Group. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014; 68: 203-15.

[27]

Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 2016; 118: 804-13.

[28]

Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology. 2017; 5: 905-13.

[29]

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95: 2536-59.

[30]

Ramachandran S, König CS, Hackett G, Livingston M, Strange RC. Managing clinical heterogeneity: An argument for benefit-based action limits. J Eng Sci Med Diagn Ther. 2018; 1: 034701.

[31]

Uchmanowicz B, Chudiak A, Mazur G. The influence of quality of life on the level of adherence to therapeutic recommendations among elderly hypertensive patients. Patient Prefer Adherence. 2018; 12: 2593-603.

[32]

Gusmai Lde F, Novato Tde S, Nogueira Lde S. A influência da qualidade de vida na adesão ao tratamento do paciente diabético: revisão sistemática [The influence of quality of life in treatment adherence of diabetic patients: a systematic review]. Rev Esc Enferm USP. 2015; 49: 839-46.

[33]

Korenman SG, Grotts JF, Bell DS, Elashoff DA. Depression in Nonclassical Hypogonadism in Young Men. J Endocr Soc. 2018; 2: 1306-13.

[34]

Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E. The association of hypogonadism with depression and its treatments. Front Endocrinol (Lausanne). 2023; 14: 1198437.

[35]

Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007; 92: 3844-53.

[36]

Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJG, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010; 73: 602-12.

PDF (1819KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉